Cryoport, Inc.Corporate Presentation

August 2016

NASDAQ: CYRX

This presentation contains certain forward-looking statements that involve risks and

uncertainties. Such forward-looking statements include statements regarding attempts to

identify new strategic opportunities which may include a strategic transaction, plans

regarding partnering activities, product pricing, financial forecasts. Such statements are

only predictions and the Company's actual results may differ materially from those

anticipated in these forward-looking statements. Factors that may cause such differences

include the risk that the Company may not be able to identify acceptable strategic

opportunities or conclude any strategic transaction which it does identify, the risk that

products that appeared promising in early use do not demonstrate the same utility in

larger-scale uses, the risks associated with the Company's reliance on outside financing to

meet its capital requirements, and the risks associated with the Company's reliance on

collaborative partners for shipping. Forward-looking statements are inherently subject to

risks and uncertainties, some of which cannot be predicted, or quantified. Future events

and actual results could differ materially from those set forth in, contemplated by, or

underlying the forward-looking statements. The risks and uncertainties to which forward-

looking statements are subject include, but are not limited to, the effect of government

regulation, competition and other material risks. These factors and others are more fully

discussed in the Company's periodic reports and other filings with the Securities and

Exchange Commission.

Safe Harbor – Forward Looking Statements

2August 2016

Transporting Life

3

Cryoport delivers comprehensive cryogenic logistics solutions

for the life sciences industry

PACKAGING

CONDITION MONITORING

INFORMATION

TECHNOLOGY

LOGISTICS EXPERTISE

August 2016

Cryoport Express® Shippersvalidated. safe. effective. efficient.

Novel liquid nitrogen dry vapor technologies

(lighter and safer than LN2 and dry ice)

Designed for fragile biologic transport

Stable cryogenic temperature below -212˚F (below the

“glass point”)

10 day “dynamic” holding time without need for

intervention

Internationale air transport association (IATA) certified,

non-hazardous and “green”

SmartPak II™ condition monitoring system which

monitors internal and external temperatures, humidity,

openings, etc.

4August 2016

SmartPak II™ Launch

Real Time Condition Monitoring

– Mapped location

– Temperature Charting

– Graphical Orientation

– Battery condition

– Pressure

– Humidity

5

Advanced Condition Monitoring System, fully integrated with the CryoportalTM to ensure complete and validated Chain-of-Condition

August 2016

6

Cryoportal™ (At the center of our information technology)

“Central nervous system” for Cryoport

• Order Entry/Processing

• Order Tracking/Management

• Inventory Tracking/Management

• Algorithms for real-time alerts and

intervention management

• Integrated with UPS, FedEx and DHL

CryoportalTM

Technology-driven Life Sciences Logistics

August 2016

Global Logistics Expertise for Life Sciences

Irvine, CA

Launched Global Temperature Controlled Logistics Consulting service

Develop customized solutions that address transport, storage, fulfillment and Information

challenges faced by life science companies

“follow the molecule” program consulting & feasibility planning for logistics

Global operations centers in strategic locations with 24/7/365 “live” support

In compliance with regulations for the life sciences logistics space

Enables clients to focus on their key competencies without the concern of complicated

Logistics requirements

7August 2016

End-to-End Solutions

8August 2016

Recent Strategic Partnerships

Global diversified metals

manufacturing company (NYSE:

WOR) with significant cryogenic

equipment manufacturing expertise

Manufactures Cryoport’s cryogenic

dewars and logistics equipment –

enables cryoport to rapidly scale to

meet client demand

9

Advanced storage and fulfillment

capabilities

Transportation of valuable, and

often irreplaceable, temperature-

sensitive biologic material

Four facilities in the United States

Enables Cryoport to offer

important elements to complete

logistics solutions

August 2016

Cryoport TARGET MarketS

(2016)

10

Regenerative Therapy Logistics Market ($1.16B)**

Clinical Trial Cold-Chain Logistics Market ($3B)*

Pharmaceutical Cold-Chain Logistics Market ($12.6B)*

Total Pharmaceutical Logistics Market ($78.8B)*

*Source: Pharmaceutical Commerce Article, March 15, 2016

**Source: Clinicaltrials.gov Database of Regenerative Therapy Companies

August 2016

Cryoport REGEN MEDICINE Market - 2016

11

*Source: Pharmaceutical Commerce Article, March 15, 2016

**Source: Nature Reviews 2013; (12) 186

$3B Clinical Trial Cold Chain Logistics Market

(2-8°C to -196°C)*

Cryoport Packaging

Opportunity is $400M

Cryoport Logistics

Opportunity is $760M

Total Bio-Storage Market is $23.9B

Regenerative Therapy Bio-

Storage Market $1.41B**Bio-Storage

Logistics Packaging

Informatics

Cryoport

$1.16 B Regenerative Therapy Cold

Chain Logistics Market

(2-8°C to -196°C)*

August 2016

Regenerative Therapy Industry

Snapshot*

12

*Source: Alliance for Regenerative Medicine Quarterly Data Report; Q2, 2016

August 2016

Clinical Trial Progression90 clinical trials – 14 phase III

13

0

10

20

30

40

50

60

70

80

90

100

2001 2002 2003 2004 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

Clinical Trials Supported by Year and Cumulative

Series1 Series2

August 2016

14

Top Clinical-stage CAR-T Projects with

Commercial Licensees (excluding China)*

*Evaluate Ltd Juune 2016 “Shifting CAR-Ts Into A Higher Gear” August 2016

Company Academic Centre Project Name

Aurora Baylor College of Medicine AU105

Autolus University College, London IRG-CART

Bellicum Baylor College of Medicine BPX-601

bluebird bio & Celgene Baylor College of Medicine bb2121

bluebird bio Uppsala University CD19 CAR

bluebird bio Baylor College of Medicine CD30 CAR

Cellectis, Pfizer, Servier University College, London UCART19

Cellular Therapeutics Christie Hospital NHS aCD19z

Cellular Therapeutics Cancer Research UK anti-CEA MFEz

Juno Fred Hutchinson & NCI JCAR014

Juno Memorial Sloan Kettering JCAR015

Juno Seattle Children's Hospital JCAR017

Juno via Opus Bio NCI JCAR018

Juno Seattle Children's Hospital JCAR023

Juno Memorial Sloan Kettering JCAR020

Juno Fred Hutchinson JCAR024

Kite Pharma Zelig Eshhar (Cabaret Biotech) KTE-C19

Kite Pharma NCI Anti-EGFRvIII CAR

Leucid Bio King's College London LEU-001

Mustang (Fortress Bio) City of Hope Medical Center MB-102

Mustang (Fortress Bio) City of Hope Medical Center MB-101

Novartis University of Pennsylvania CART-BCMA

Novartis Universtiy of Pennsylvania CTL019

Novartis Universtiy of Pennsylvania CTL119

Novartis University of Pennsylvania CART22 cells

Novartis University of Pennsylvania CART-EGFRvIII

Novartis Universtiy of Pennsylvania CART-meso

Ziopharm, Intrexon, Merck MD Anderson Cancer Center CD19 CAR

August 2016

15

End-to-End Solution

From point of origin to point of destination, Cryoport will provide a fully validated solution, including primary and

secondary packaging, shipping, continuous tracking and monitoring, documentation assistance and 24/7

support.

Steadfast Protection

Navigate cold chain logistics with fully validated Cryoport Express® liquid nitrogen dry vapor shippers that are

being tested and certified after every shipment.

Nonstop Monitoring

Complete visibility and transparency with our CryoportalTM logistics management system and

SmartPak/SmartPak II condition monitoring system. All chain-of-condition and chain-of-custody data for every

single shipment resides in a secure, cloud-based system.

Intelligent Logistics

With over 100,000 cryogenic shipments in and out of over 100 countries, we have unparalleled logistics experience.

Our CryoportalTM, shipping data algorythms and experience enable us to select the best partner from our global

network of integrators, freight forwarders and specialized logistics companies for specific shipping lanes.

24/7 Live Global Support

We provide 24/7 live global support for your complete cold chain logistics needs.

Complete Compliance

Cryoport helps ensure that shipments are in compliance with all applicable regulations. Cryoport’s team of

experts will guide through customs and can manage all documentation.

Risk Mitigation

Our solution is designed to maintain integrity of your materials and data throughout the transit through

purpose built equipment, information technology and proactive monitoring and intervention capabilities by our

experienced cold chain logistics team.

Why Life Science Companies choose Cryoport?

August 2016 15

16

Markets We Serve

Animal HealthReproductive

MedicineBiopharma

August 2016 16

Revenue Trends

17August 2016

18

continuing strong double-digit growth year-over-year and

sequentially…

Q1 FY2017 Revenue Trends(quarter ended June 30, 2016)

+74% +50% +30% +34%

August 2016

SummaryQ1 2017 revenue increased 34% year-over-year

Recently announced first commercial biopharma support

agreement

Supporting 23 of the 28 leading clinical stage CAR-T projects

Over 550 clients; including 28 new biopharma clients in

FYQ1

“powered by cryoport” from FedEx, UPS, and DHL

Cellular therapy market projected to grow to $11.8 billion by

2020

Over 30,000 shipments through 90 countries

Sustainable and growing first-to-market advantage with

growing array of advanced logistics solutions

19August 2016

Board of Directors & Management

Board of Directors

Jerrell Shelton, Chairman of the Board

Richard Berman, Lead Director, Chairman of Audit and Compensation Committees

Robert Hariri, PhD, MD, Director

Ramkumar Mandalam, Ph.D., Director

Edward Zecchini, Chairman of the Nominating and Governance Committee

Management

Jerrell Shelton, CEO

Robert Stefanovich, Chief Financial Officer

Mark W. Sawicki, Ph.D., Chief Commercial Officer

Tamie Joeckel, Senior Vice President Client Services

Bret Bollinger, Vice President Operations

Thomas Heinzen, Vice President Corporate Development

20August 2016

21August 2016

HQ Interior

22August 2016

HQ Interior

23August 2016

HQ Interior

24August 2016

High Volume Shipper

25August 2016

Science. Logistics. Certainty.

NASDAQ: CYRX